Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedMar 21, 2026
DataAggregated Company Financials
Companies315
  • 7D-3.9%
  • 3M-1.5%
  • 1Y18.2%
  • YTD-2.4%

Over the last 7 days, the Pharma industry has dropped 3.9%, driven by a pullback from Eli Lilly of 8.0%. This takes the industry's 12 month performance to a gain of 18%. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 21 Mar 2026US$2.2tUS$406.2bUS$72.0b16.6x30.9x5.5x
Mon, 16 Feb 2026US$2.4tUS$411.4bUS$73.9b20.2x32.3x5.8x
Wed, 14 Jan 2026US$2.3tUS$402.6bUS$71.5b20.5x32x5.7x
Fri, 12 Dec 2025US$2.1tUS$402.8bUS$71.4b19.9x30.1x5.3x
Sun, 09 Nov 2025US$2.0tUS$396.3bUS$70.8b17.9x27.7x4.9x
Tue, 07 Oct 2025US$1.9tUS$387.9bUS$60.9b19.2x31.7x5x
Thu, 04 Sep 2025US$1.8tUS$387.9bUS$61.0b19.5x29.2x4.6x
Sat, 02 Aug 2025US$1.7tUS$381.9bUS$55.1b17.8x30.7x4.4x
Mon, 30 Jun 2025US$1.7tUS$382.7bUS$61.2b17.5x27.9x4.5x
Wed, 28 May 2025US$1.6tUS$382.6bUS$61.2b17.5x26.9x4.3x
Fri, 25 Apr 2025US$1.7tUS$380.6bUS$48.4b16.1x35.9x4.6x
Sun, 23 Mar 2025US$1.9tUS$381.1bUS$41.3b17x45.6x4.9x
Tue, 18 Feb 2025US$1.8tUS$380.9bUS$39.0b18.1x46.9x4.8x
Thu, 16 Jan 2025US$1.8tUS$369.3bUS$31.2b18.5x56.4x4.8x
Sat, 14 Dec 2024US$1.8tUS$373.8bUS$30.6b18.4x59.1x4.8x
Mon, 11 Nov 2024US$1.9tUS$373.7bUS$30.3b21.4x62.8x5.1x
Wed, 09 Oct 2024US$2.0tUS$364.1bUS$25.2b18.2x78.7x5.5x
Fri, 06 Sep 2024US$2.1tUS$364.1bUS$25.5b17.9x80.7x5.6x
Sun, 04 Aug 2024US$1.9tUS$359.3bUS$22.1b15.8x86.8x5.3x
Tue, 02 Jul 2024US$1.9tUS$357.6bUS$13.8b16x140.9x5.4x
Thu, 30 May 2024US$1.9tUS$358.3bUS$14.1b15.8x132x5.2x
Sat, 27 Apr 2024US$1.8tUS$359.5bUS$17.5b22.4x102.8x5x
Mon, 25 Mar 2024US$1.9tUS$355.3bUS$22.6b19.8x82.6x5.3x
Wed, 21 Feb 2024US$1.9tUS$355.0bUS$23.9b28.5x78.6x5.3x
Fri, 19 Jan 2024US$1.7tUS$375.2bUS$33.9b27.7x51.6x4.7x
Sun, 17 Dec 2023US$1.6tUS$375.1bUS$33.9b26.7x48.6x4.4x
Tue, 14 Nov 2023US$1.6tUS$375.5bUS$34.1b26.5x48x4.4x
Thu, 12 Oct 2023US$1.7tUS$381.8bUS$43.8b17.1x39x4.5x
Sat, 09 Sep 2023US$1.8tUS$381.8bUS$43.9b19.1x41.3x4.7x
Mon, 07 Aug 2023US$1.7tUS$379.8bUS$43.1b20.5x39.1x4.4x
Wed, 05 Jul 2023US$1.7tUS$392.8bUS$60.2b18.6x29x4.4x
Fri, 02 Jun 2023US$1.7tUS$393.0bUS$60.5b18.3x27.9x4.3x
Sun, 30 Apr 2023US$1.7tUS$400.2bUS$62.2b17.4x27x4.2x
Tue, 28 Mar 2023US$1.6tUS$401.2bUS$69.5b14.7x22.5x3.9x
Price to Earnings Ratio

22.5x


Total Market Cap: US$1.6tTotal Earnings: US$69.5bTotal Revenue: US$401.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 30.9x which is lower than its 3-year average PE of 53.5x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.5x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.86%
Healthcare-2.34%
Pharma-3.90%
Pharma-3.90%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
PFE PfizerUS$26.971.5%
+US$2.2b		2.6%PE19.8x
RGC Regencell Bioscience HoldingsUS$27.3717.8%
+US$2.0b		1,673.9%PB2784.6x
ELAN Elanco Animal HealthUS$23.984.5%
+US$517.1m		127.7%PS2.5x
CORT Corcept TherapeuticsUS$34.647.7%
+US$264.9m		-40.9%PE37.5x
MANE VeradermicsUS$58.8911.5%
+US$227.4m		n/aPE-35.7x

Latest News

BMY
US$57.48
Bristol-Myers Squibb
7D
-2.7%
1Y
-5.9%
TEVA
US$28.73
Teva Pharmaceutical Industries
7D
0.6%
1Y
78.4%
PFE
US$26.97
Pfizer
7D
1.5%
1Y
2.6%
LLY
US$906.70
Eli Lilly
7D
-8.0%
1Y
8.3%
MRK
US$114.18
Merck
7D
-1.2%
1Y
22.6%
JNJ
US$235.37
Johnson & Johnson
7D
-2.5%
1Y
43.8%

Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability

Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?
GPCR
US$48.59
Structure Therapeutics
7D
-9.6%
1Y
131.7%
JAZZ
US$180.62
Jazz Pharmaceuticals
7D
1.2%
1Y
30.2%

JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks

The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.
CORT
US$34.64
Corcept Therapeutics
7D
7.7%
1Y
-40.9%

CORT: Future Generic Ruling And Oncology Data Will Drive Upside

Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.
ELAN
US$23.98
Elanco Animal Health
7D
4.5%
1Y
127.7%
WVE
US$11.76
Wave Life Sciences
7D
-9.7%
1Y
22.6%

WVE: Obesity Fat Reduction Data Will Drive Future Upside Potential

Analysts have inched their fair value estimate for Wave Life Sciences higher from $33.38 to $33.50. This reflects updated views on WVE-007's obesity program and potential regulatory pathways, as well as the recent cluster of higher Street price targets that highlight upcoming data as a key near term catalyst.
VTRS
US$13.20
Viatris
7D
-2.3%
1Y
44.3%

VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations

Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.
BLTE
US$154.59
Belite Bio
7D
-5.8%
1Y
129.8%

Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech

Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?
TERN
US$48.44
Terns Pharmaceuticals
7D
4.1%
1Y
1,346.0%
RGC
US$27.37
Regencell Bioscience Holdings
7D
17.8%
1Y
1,673.9%

Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility

If you're looking for a stock that perfectly embodies the wild, speculative side of the market for your viewers, Regencell Bioscience (RGC) is it. As of late February 2026, this Hong Kong-headquartered, early-stage bioscience company is trading around $29.17 , following a period of mind-bending volatility where the stock surged thousands of percent over the past year.
MANE
US$58.89
Veradermics
7D
11.5%
1Y
n/a